Abstract:Highly prothrombotic, platelet activating PF4-dependent anti-PF4 antibodies can occur without preceding heparin or vaccination. These antibodies are not heparin-dependent, differ from spontaneous HIT and occurred already before 2020. Platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies and anti-PF4 antibodies cause heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT), respectively. Diagnostic and treatment considerations differ somewhat between HIT and VITT. We identified patients with thrombocytopenia and thrombosis without proximate heparin exposure or adenovirus-based vaccination who tested strongly positive by PF4/polyanion EIA and negative/weakly-positive by heparin-induced platelet activation (HIPA) test but strongly positive by PF4-induced platelet activation (PIPA) test (i.e., VITT-like profile). We tested these patients by a standard chemiluminescence assay that detects anti-PF4/heparin antibodies found in HIT (HemosIL ® AcuStar HIT-IgG (PF4-H) ) as well as a novel chemiluminescence assay for anti-PF4 antibodies found in VITT. Representative control sera included an exploratory anti-PF4 antibody-positive but HIPA-negative/weak cohort obtained prior to 2020 (n=188). We identified 9 patients with a clinical-pathological profile of a VITT-like disorder in the absence of proximate heparin or vaccination, with a high frequency of stroke (arterial, n=3; cerebral venous sinus thrombosis, n=4), thrombocytopenia (median platelet count nadir, 49×10 9 /L), and hypercoagulability (greatly elevated D-dimer levels). VITT-like serological features included strong reactivity by PIPA (aggregation <10min in 9/9 sera) and positive testing in the novel anti-PF4 chemiluminescence assay (3/9 also tested positive in the anti-PF4/heparin chemiluminescence assay). Our exploratory cohort identified 13 additional patient sera obtained before 2020 with VITT-like anti-PF4 antibodies. Platelet-activating VITT-like anti-PF4 antibodies should be considered in patients with thrombocytopenia, thrombosis and very high D-dimer levels, even without a proximate exposure to heparin or adenovirus vector vaccines.

The immunology of PF4 polyanion interactions

Platelet factor 4(PF4) and its multiple roles in diseases

New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF

Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder

Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity

Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes

Molecular architecture and platelet-activating properties of small immune complexes assembled on heparin and platelet factor 4

Anti-PF4 antibodies and their relationship with COVID infection

Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disorders

The role of fluid-phase immune complexes in the pathogenesis of heparin-induced thrombocytopenia

Association of Metal Cations with the Anti-PF4/Heparin Antibody Response in Heparin-Induced Thrombocytopenia

Defining an Antigenic Epitope on Platelet Factor 4 Associated with Heparin-Induced Thrombocytopenia

Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin

[Management of HIT/anti-PF4 disorders]

Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure

Activated platelets kill Staphylococcus aureus, but not Streptococcus pneumoniae-The role of FcγRIIa and platelet factor 4/heparinantibodies

Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis

Frequency and Clinical Impact of Platelet Factor 4-Specific Antibodies in Patients Undergoing Extracorporeal Membrane Oxygenation

Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review

Critical role of CD4 T cells in PF4/heparin antibody production in mice